Patents by Inventor Taeko Shinozaki
Taeko Shinozaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230074669Abstract: The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.Type: ApplicationFiled: November 24, 2021Publication date: March 9, 2023Applicant: Daiichi Sankyo Company, LimitedInventors: Kenji Yoshikawa, Noriyasu Haginoya, Tomoaki Hamada, Ryutaro Kanada, Jun Watanabe, Yoshiko Kagoshima, Eri Tokumaru, Kenji Murata, Takayuki Baba, Mayumi Kitagawa, Akiko Kurimoto, Masashi Numata, Machiko Shiroishi, Taeko Shinozaki
-
Publication number: 20230030720Abstract: The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.Type: ApplicationFiled: December 5, 2019Publication date: February 2, 2023Applicant: Daiichi Sankyo Company, LimitedInventors: Kenji Yoshikawa, Noriyasu Haginoya, Tomoaki Hamada, Ryutaro Kanada, Jun Watanabe, Yoshiko Kagoshima, Eri Tokumaru, Kenji Murata, Takayuki Baba, Mayumi Kitagawa, Akiko Kurimoto, Masashi Numata, Machiko Shiroishi, Taeko Shinozaki
-
Patent number: 11236106Abstract: The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.Type: GrantFiled: April 28, 2021Date of Patent: February 1, 2022Assignee: Daiichi Sankyo Company, LimitedInventors: Kenji Yoshikawa, Noriyasu Haginoya, Tomoaki Hamada, Ryutaro Kanada, Jun Watanabe, Yoshiko Kagoshima, Eri Tokumaru, Kenji Murata, Takayuki Baba, Mayumi Kitagawa, Akiko Kurimoto, Masashi Numata, Machiko Shiroishi, Taeko Shinozaki
-
Publication number: 20210269454Abstract: The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.Type: ApplicationFiled: April 28, 2021Publication date: September 2, 2021Applicant: Daiichi Sankyo Company, LimitedInventors: Kenji Yoshikawa, Noriyasu Haginoya, Tomoaki Hamada, Ryutaro Kanada, Jun Watanabe, Yoshiko Kagoshima, Eri Tokumaru, Kenji Murata, Takayuki Baba, Mayumi Kitagawa, Akiko Kurimoto, Masashi Numata, Machiko Shiroishi, Taeko Shinozaki
-
Patent number: 10221195Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I): wherein R1 represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R2 and R3 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R4 and R5 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R6 represents a hydrogen atom or the like, each R7 may be the same or different and may each represent an optionally substituted C1-6 alkoxy group or the like, X represents —CH?, —C(—R7)?, or —N?, and m represents 1 to 4, or a pharmacologically acceptable salt thereof.Type: GrantFiled: January 18, 2018Date of Patent: March 5, 2019Assignees: Daiichi Sankyo Company, Limited, Sanford Burnham Prebys Medical Discovery InstituteInventors: Shojiro Miyazaki, Yuko Yamamoto, Keisuke Suzuki, Masaharu Inui, Masanori Izumi, Kaori Soma, Anthony Pinkerton, Taeko Shinozaki
-
Publication number: 20180141960Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I): wherein R1 represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R2 and R3 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R4 and R5 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R6 represents a hydrogen atom or the like, each R7 may be the same or different and may each represent an optionally substituted C1-6 alkoxy group or the like, X represents —CH?, —C(—R7)?, or —N?, and m represents 1 to 4, or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: January 18, 2018Publication date: May 24, 2018Applicants: Daiichi Sankyo Company, Limited, Sanford Burnham Prebys Medical Discovery InstituteInventors: Shojiro Miyazaki, Yuko Yamamoto, Keisuke Suzuki, Masaharu Inui, Masanori Izumi, Kaori Soma, Anthony Pinkerton, Taeko Shinozaki
-
Patent number: 9920068Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I): wherein R1 represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R2 and R3 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R4 and R5 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R6 represents a hydrogen atom or the like, each R7 may be the same or different and may each represent an optionally substituted C1-6 alkoxy group or the like, X represents —CH?, —C(—R7)?, or —N?, and m represents 1 to 4, or a pharmacologically acceptable salt thereof.Type: GrantFiled: July 7, 2016Date of Patent: March 20, 2018Assignees: Daiichi Sankyo Company, Limited, Sanford Burnham Prebys Medical Discovery InstituteInventors: Shojiro Miyazaki, Yuko Yamamoto, Keisuke Suzuki, Masaharu Inui, Masanori Izumi, Kaori Soma, Anthony Pinkerton, Taeko Shinozaki
-
Patent number: 9879032Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I): wherein R1 represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R2 and R3 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R4 and R5 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R6 represents a hydrogen atom or the like, each R7 may be the same or different and may each represent an optionally substituted C1-6 alkoxy group or the like, X represents —CH?, —C(—R7)?, or —N?, and m represents 1 to 4, or a pharmacologically acceptable salt thereof.Type: GrantFiled: April 6, 2017Date of Patent: January 30, 2018Assignees: Daiichi Sankyo Company, Limited, Sandford Burnham Prebys Medical Discovery InstituteInventors: Shojiro Miyazaki, Yuko Yamamoto, Keisuke Suzuki, Masaharu Inui, Masanori Izumi, Kaori Soma, Anthony Pinkerton, Taeko Shinozaki
-
Publication number: 20170240562Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I): wherein R1 represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R2 and R3 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R4 and R5 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R6 represents a hydrogen atom or the like, each R7 may be the same or different and may each represent an optionally substituted C1-6 alkoxy group or the like, X represents —CH?, —C(—R7)?, or —N?, and m represents 1 to 4, or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: July 7, 2016Publication date: August 24, 2017Applicants: Daiichi Sankyo Company, Limited, Sanford Burnham Prebys Medical Discovery InstituteInventors: Shojiro Miyazaki, Yuko Yamamoto, Keisuke Suzuki, Masaharu Inui, Masanori Izumi, Kaori Soma, Anthony Pinkerton, Taeko Shinozaki
-
Publication number: 20170210755Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I): wherein R1 represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R2 and R3 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R4 and R5 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R6 represents a hydrogen atom or the like, each R7 may be the same or different and may each represent an optionally substituted C1-6 alkoxy group or the like, X represents —CH?, —C(—R7)?, or —N?, and m represents 1 to 4, or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: April 6, 2017Publication date: July 27, 2017Applicants: Daiichi Sankyo Company, Limited, Sanford Burnham Prebys Medical Discovery InstituteInventors: Shojiro Miyazaki, Yuko Yamamoto, Keisuki Suzuki, Masaharu Inui, Masanori Izumi, Kaori Soma, Anthony Pinkerton, Taeko Shinozaki